Altimmune, Inc. (FRA:3G0)
Germany · Delayed Price · Currency is EUR 4.500
+0.146 (3.35%)
At close: Nov 28, 2025
Altimmune Company Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis.
The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.
| Country | United States |
| Founded | 1997 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 59 |
| CEO | Vipin Garg |
Contact Details
Address: 910 Clopper Road Gaithersburg, Delaware 20878 United States | |
| Phone | 240 654 1450 |
| Website | altimmune.com |
Stock Details
| Ticker Symbol | 3G0 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Vipin Garg | Chief Executive Officer |
| Gregory Weaver | Chief Financial Officer |